A5101775982- RNA Interference and Gene Delivery
- CAR-T cell therapy research
- Sarcoma Diagnosis and Treatment
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Cell Adhesion Molecules Research
- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- 3D Printing in Biomedical Research
- Cancer Cells and Metastasis
- Nanoparticle-Based Drug Delivery
- Birth, Development, and Health
- Lung Cancer Research Studies
- Acute Kidney Injury Research
- Lymphoma Diagnosis and Treatment
- Hypothalamic control of reproductive hormones
- Immune Cell Function and Interaction
- Cancer, Lipids, and Metabolism
- Advanced Biosensing Techniques and Applications
- T-cell and B-cell Immunology
- Sepsis Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- MicroRNA in disease regulation
The University of Texas MD Anderson Cancer Center
2020-2023
Texas A&M Health Science Center
2021
Tianjin Medical University
2017
Baylor Scott & White Health
2014
Temple College
2014
Baylor University
2013
Adoptive T-cell transfer has become an attractive therapeutic approach for hematological malignancies but shows poor activity against large and heterogeneous solid tumors. Interleukin-12 (IL-12) exhibits potent antitumor efficacy tumors, its clinical application been stalled because of toxicity. Here, we aimed to develop a safe IL-12 therapy eliminating tumors.We generated cell membrane-anchored (aIL12), tumor-targeted (ttIL12), ttIL-12 (attIL12) armed T cells, chimeric antigen receptor-T...
Abstract Although tissue-resident memory T (T RM ) cells specific for previously encountered pathogens have been characterized, the induction and recruitment of brain following immune therapy has not observed in context glioblastoma. Here, we show that expressing fibrinogen-like 2 (FGL2)–specific single-chain variable fragments (T-αFGL2) can induce tumor-specific CD8 + prevent glioblastoma recurrence. These display a highly expanded cell receptor repertoire distinct from found peripheral...
Neuroblastoma (NB) is a deadly childhood disease that carries 50% chance of relapse for anyone in remission and similar level 5-year survival. We investigated the value our proprietary approach—cell surface vimentin (CSV) positive circulating tumor cells (CTC) to monitor treatment response predict NB patients under Phase II long-term preventative clinical trial. longitudinally analyzed peripheral blood samples from 93 27 cycles (~25 months) discovered presence CSV+ CTCs first two sequential...
Tumors of the central nervous system (CNS) are most common and lethal childhood malignancy. Detection residual disease longitudinal monitoring treatment response in patients challenging rely on serial imaging. This current standard care fails to detect microscopic or provide molecular characteristics tumors. As such, there is dire need for minimally invasive liquid biopsy techniques. We have previously shown high specificity using cell surface vimentin (CSV) identify circulating tumor cells...
Despite advances in care, the 5 year overall survival for patients with relapsed and or metastatic sarcoma remains as low < 35%. Currently, there are no biomarkers available to assess disease status sarcomas such, surveillance reliant on serial imaging which increases risk of secondary malignancies heightens patient anxiety.Here, first time reported literature, we have enumerated cell surface vimentin (CSV+) CTCs blood 92 pediatric adolescent young adult (AYA) a possible marker disease.We...
In this report, we investigate the toxicity of ionophore thiomaltol (Htma) and Cu salts to melanoma. Divalent metal complexes display against A375 melanoma cell culture resulting in a distinct apoptotic response at submicromolar concentrations, with Cu(tma)2 > Zn(tma)2 >> Ni(tma)2. metal-chelated media, Htma treatment shows little toxicity, but combination supplemental CuCl2, termed Cu/Htma treatment, results that increases suprastoichiometric concentrations CuCl2 correlates accumulation...
Abstract Background Adoptive T-cell transfer has become an attractive therapeutic approach for hematologic malignancies but shows poor activity against large and heterogeneous solid tumors. Interleukin-12 (IL-12) potent antitumor efficacy tumors, its clinical application been stalled because of toxicity. Here, we aimed to develop a safe IL-12 therapy eliminating Methods We generated cell membrane-anchored (aIL12), tumor-targeted (ttIL12), (attIL12) armed T cells, CAR-T TCR-T cells with each....
Abstract BACKGROUND Despite its increasing use, circulating tumor cells (CTCs) have not been studied in pediatric brain tumors. METHODS Cell surface vimentin (CSV) is a marker for CTC detection. We developed an automated CSV-based capture method using the Abnova Cytoquest platform. PBMCs isolated from blood samples 52 patients were processed to isolate CSV+ CTCs. Captured then stained CSV and CD45 scanned determine number of DIPG additionally examined H3K27M expression on cells. Long term...
Glioblastoma multiforme (GBM) is an aggressive malignant brain tumor with poor prognosis. Like other difficult-to-treat cancers, GBM utilizes glucose (glycolysis) at a high rate (the Warburg effect), but can adapt to stresses or starvation by using alternatives, including fatty acids amino acids, as mitochondrial substrates. The unique features of GBM-specific metabolism may serve novel therapeutic targets. Temozolomide (TMZ), along surgery and radiation, are current standards for treating...
BACKGROUND AND SIGNIFICANCE: Glioblastoma Multiforme (GBM) is a deadly and highly aggressive brain tumor with grim prognosis. At present none of the treatment strategies extend life most patients beyond year. A contribution from immune system in control and/or growth tumors currently under intense investigation. However, GBM cells use to hide are poorly understood. EXPERIMENTAL APPROACH: To address this issue, we compared graft acceptance mouse 261 neurosphere (mouse glioma cell line/derived...
<div>AbstractPurpose:<p>Chimeric antigen receptor (CAR) T-cell therapy has shown great promise for treating hematologic malignancies but requires a long duration of expansion, is associated with severe toxicity, and limited efficacy solid tumors. We designed experiments to address those challenges.</p>Experimental Design:<p>We generated cell membrane-anchored tumor-targeted IL12 (attIL12) arm peripheral blood mononuclear cells (PBMC) instead T omit the expansion phase...
<div>AbstractPurpose:<p>Chimeric antigen receptor (CAR) T-cell therapy has shown great promise for treating hematologic malignancies but requires a long duration of expansion, is associated with severe toxicity, and limited efficacy solid tumors. We designed experiments to address those challenges.</p>Experimental Design:<p>We generated cell membrane-anchored tumor-targeted IL12 (attIL12) arm peripheral blood mononuclear cells (PBMC) instead T omit the expansion phase...
e19026 Background: Treatment guidance and decision making according to modified RECIST guidelines often depends on characterization of these biomarkers in patients with cancer. Although panels larger breadths coverage are useful for initial detection evaluation disease burden prognosis, their cost-effectiveness decreases as treatment progress; smaller subpanels may yield equally valuable information into progress guide a more cost-effective manner, potentially leading datapoints comparison...
e18537 Background: Patients with CTCL-MF are treated a variety of approaches by varying clinical specialists. None the current is curative. This study was conducted to understand most common treatment practices for later stages in United States. Methods: An internet-based panel 50 oncologists and dermatologists provided over 1100 independent decisions from all disease stages. Those intermediate (stage IIb) advanced (stages III / IVa IVb) were used determine representative US. Results:...
Supplementary Figure from Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma
Supplementary Figure from Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma
Supplementary Figure from Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma
Supplementary Figure from Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma
Abstract Tissue-resident memory T cells (T RM ) specific to previously encountered pathogens have been characterized, but tumor-specific in brain not reported the literature. We discovered that armed with FGL2-blocking single-chain variable fragments (T-αFGL2) are able induce CD8 + cells, which prevent glioblastoma recurrence, a major obstacle achieving long term survivors. These displayed unique highly expanded cell receptor repertoire distinct from found peripheral tissues. Notably, these...